Vivus Announces Enrollment Of First Patient In Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine As A Component Of High-Dose Chemotherapy Prior To Transplant In Patients With Hodgkin Or Non-Hodgkin Lymphoma
ReutersApr 14, 2025 2:16 PM
April 14 (Reuters) -
VIVUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL ASSESSING ETHANOL-FREE CARMUSTINE AS A COMPONENT OF HIGH-DOSE CHEMOTHERAPY PRIOR TO TRANSPLANT IN PATIENTS WITH HODGKIN OR NON-HODGKIN LYMPHOMA
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Tesla's 2025 Q1 Earning Report Preview: A Critical Moment of Hope and Challenge
Tesla's 2025 Q1 financial report will be released on April 22. As a leader in the global electric vehicle industry, its performance has attracted much attention from the market.TradingKey
11 hours ago
Enphase Energy (ENPH) Q1 2025 Earnings Preview: Solar Innovations Amid Market Fluctuations
TradingKey - Enphase Energy (ENPH) will report Q1 2025 results on April 22, 2025, after market close. The guidance is $340 million to $380 million of revenue, excluding safe harbor revenue of $50 million.TradingKey
14 hours ago
Goldman Sachs: Repricing Resilience Amidst Strategic Reinvention
TradingKey - Goldman Sachs (GS) steps into Q2 2025 with a mix of operational rebound and long-term readjustment, offering investors a multifaceted but intriguing enigma.TradingKey
17 hours ago
Understanding the Fed’s Overnight Reverse Repo(RRP), What Is the Relationship Between QT and Debt Ceiling
TradingKey - As the U.S. enters a new rate cycle, the quantitative tightening (QT)—initially launched to reduce the Federal Reserve’s bloated balance sheet following the COVID-19 pandemic—is also nearing its conclusion. A key metric in gauging when to end QT is the scale of the Fed’s ON RRP...TradingKey
22 hours ago
ASML: The Cyclical Titan at the Heart of AI’s Next Chapter
TradingKey - Amidst the choppy macroeconomic environment and increasing geopolitical tension, ASML's (ASML) Q1 2025 results highlight its seemingly paradoxical position as both a cyclical capital equipment provider to the semiconductor industry and an essential facilitator of secular AI expansion.TradingKey
22 hours ago
